Welcome to our dedicated page for Catalent news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent stock.
Catalent Inc (NYSE: CTLT) delivers essential pharmaceutical development solutions and manufacturing services for global healthcare partners. This dedicated news hub provides investors and industry professionals with timely updates on Catalent's operational milestones, strategic initiatives, and regulatory developments.
Access authoritative reporting on material events including clinical manufacturing advancements, drug delivery innovations, and global supply chain expansions. Our curated collection features earnings disclosures, partnership announcements, and facility updates directly impacting Catalent's market position.
Key focus areas include bioavailability enhancement technologies, commercial packaging solutions, and biologics manufacturing capabilities. Monitor critical updates through verified press releases and objective analysis of Catalent's role in accelerating therapeutic development timelines.
Bookmark this page for streamlined tracking of CTLT's progress in formulation science, regulatory submissions, and capacity investments across its global manufacturing network.
Catalent has appointed three new directors to its Board: Susan Mahony, Marie-France Tschudin, and Tim Walbert, as the company continues its growth under Novo Holdings' ownership. The appointments are effective immediately and complete the company's Board updates, bringing the total to 7 directors.
The Board also includes Jonathan Levy (Senior Partner) and Charles Patten (Partner) from Novo Holdings, who joined following Catalent's transition to a private company after its acquisition by Novo Holdings in December 2024. Alessandro Maselli, President and CEO, expressed enthusiasm about working with the new Board members to drive continued growth as an independent CDMO.
Board Chair John Greisch highlighted that these biopharma leaders' expertise in navigating healthcare complexities will be valuable for Catalent's mission to develop, manufacture, and supply products that improve people's lives.
Novo Holdings has completed its acquisition of Catalent in an all-cash transaction valued at approximately $16.5 billion. Under the deal, Catalent shareholders will receive $63.50 per share, representing a 47.5% premium to the 60-day volume-weighted average price as of February 2, 2024. Following the acquisition, Catalent will operate as a private company, with Alessandro Maselli continuing as President and CEO.
As part of the transaction, Novo Nordisk will acquire three fill-finish sites from Novo Holdings, located in Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium. Catalent's common stock will be delisted from the New York Stock Exchange.
Catalent (NYSE: CTLT) and Novo Holdings have announced the fulfillment of all regulatory closing conditions for their pending transaction, with closure expected in the coming days. The transition will move Catalent to private ownership under Novo Holdings, a global life sciences investment firm.
Alessandro Maselli, Catalent's CEO, expressed optimism about the company's future, noting that Novo Holdings' support and additional resources will strengthen Catalent's position to drive innovation and enhance offerings for customers and patients. Jonathan Levy, Senior Partner at Novo Holdings, emphasized the transaction's expected benefits and their enthusiasm for partnering with Catalent to improve patient outcomes.
Catalent (NYSE: CTLT) and Novo Holdings have received unconditional approval from the European Commission for their pending acquisition transaction. The deal, which will see Novo Holdings acquire Catalent, is expected to close towards the end of 2024, subject to remaining regulatory clearances and customary closing conditions.
Alessandro Maselli, Catalent's CEO, expressed optimism about the company's future as a private entity under Novo Holdings' support. Jonathan Levy, Senior Partner at Novo Holdings, emphasized their commitment to supporting Catalent's continued value creation for stakeholders and improved outcomes for customers and patients.
Catalent (CTLT) reported Q1 fiscal 2025 results with net revenue of $1.02 billion, up 4% year-over-year. Excluding COVID revenue, which decreased from ~$100M to ~$30M, core revenue grew 13%. The company reported a net loss of $(129) million, or $(0.71) per share, while Adjusted EBITDA increased 11% to $125 million. The Biologics segment revenue grew 3% to $461 million, while Pharma and Consumer Health revenue increased 5% to $563 million. The company maintains its pending transaction with Novo Holdings, valued at $16.5 billion, expected to close by end of 2024.
Catalent has issued an open letter to customers addressing inaccuracies about Novo Holdings' pending acquisition. Key points include:
- Catalent will continue as a leading global, independent, full-service CDMO post-acquisition
- The company's network of nearly 50 global sites will maintain its services and partnerships
- Alessandro Maselli will remain President and CEO after the transaction closes
- Novo Holdings is committed to supporting Catalent's growth and customer service
- Catalent's commitments to customers and patient focus will not change
- The acquisition is expected to close towards the end of 2024, subject to regulatory approvals
Catalent, Inc. (NYSE: CTLT) has announced an agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO). The deal is expected to close in early 2025, with financial details undisclosed. Catalent's corporate headquarters, currently located at the Somerset site, will transition to a new location to be announced later.
This move follows Catalent's recent investments in oral solid capabilities at other facilities in the United States and Europe, including expanded commercial spray drying capabilities, oral high potent API handling capabilities, and manufacturing capacity. A notable investment was the acquisition of a 333,000-square-foot facility in Greenville, NC for $475 million in October 2022, which specializes in turnkey solutions for oral solid dosage forms.
Catalent (NYSE: CTLT) reported Q4'24 net revenue of $1.30 billion, a 23% increase from Q4'23, or 24% in constant currency. Excluding COVID-related revenue, this growth was 29%.
Fiscal 2024 net revenue was $4.38 billion, a 3% increase from FY'23, or 2% in constant currency. Excluding COVID-related revenue, growth was 13%.
Q4'24 net earnings were $23 million, with an adjusted EBITDA of $305 million, up 150% from Q4'23. Fiscal 2024 saw a net loss of $1.04 billion, with adjusted EBITDA of $703 million, a 1% increase from FY'23.
Biologics segment Q4'24 net revenue rose 51%, while Pharma and Consumer Health increased by 7%. Catalent's total debt stood at $4.91 billion as of June 30, 2024.
The pending $16.5 billion acquisition by Novo Holdings is expected to close by the end of 2024.
Catalent, Inc. (NYSE: CTLT) has completed a $25 million expansion of its clinical supply facility in Schorndorf, Germany. The expansion adds 32,000 square feet of space, increasing capacity for temperature-controlled storage between 15-25°C and creating room for a new automatic bottle filling line. It also includes a dedicated area for Catalent's FastChain® demand-led supply service.
The Schorndorf site, Catalent's flagship European facility, offers comprehensive clinical supply services, including packaging, storage, and distribution. This expansion aims to support Catalent's pharma and biotech customers and enhance its ability to meet growing demand for clinical packaging solutions.
Ardena announces the retirement of CEO Harry Christiaens and the appointment of Jeremie Trochu as the new CEO, effective June 6, 2024. Trochu, an experienced executive, previously served at Catalent as Division Head, Bioanalytics. He brings over 20 years of expertise in the pharmaceutical CDMO industry and has extensive experience in both European and North American markets. Harry will remain on Ardena's Board after stepping down. GHO Capital, which acquired Ardena in 2019, expressed confidence in Trochu's ability to drive growth and international expansion. The announcement follows Ardena's recent EUR 25 million investment in GMP nanomedicine and aseptic fill-finish capabilities.
